Journal Mobile Options
Table of Contents
Vol. 31, No. 5, 2008
Issue release date: December 2008
Kidney Blood Press Res 2008;31:322–329

Effects of Long-Term Cholecalciferol Supplementation on Mineral Metabolism and Calciotropic Hormones in Chronic Kidney Disease

Okša A. · Spustová V. · Krivošíková Z. · Gazdíková K. · Fedelešová V. · Lajdová I. · Štefíková K. · Bernasovská G. · Žilinská Z. · Dzúrik R.
aDepartment of Clinical and Experimental Pharmacotherapy, Slovak Health University, and bDérer’s University Hospital, Bratislava, Slovakia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Data on the efficacy and safety of long-term vitamin D supplementation in chronic kidney disease (CKD) are scarce. We assessed the effects of the 12-month vitamin D3 treatment on mineral metabolism and calciotropic hormones in patients with CKD stages 2–4. Methods: Eighty-seven patients (mean age 66 years, men/women 33/54) were randomized to cholecalciferol treatment with either 5,000 or 20,000 IU/week. Serum calcium, phosphate, 25(OH)D3, 1,25(OH)2D3, PTH and urinary mineral concentrations were obtained at baseline and after 4, 8 and 12 months. Results: The median serum mineral concentrations were normal and not changed throughout the study. The number of hypercalciuric patients slightly increased with higher dose, but no sustained rise in calciuria was present. Vitamin D insufficiency/deficiency was revealed in 72 (83%) patients at baseline and 37 (43%) at month 12. The 25(OH)D3 levels increased more with higher dose; a rise in 1,25(OH)2D3 was less impressive. The parathyroid hormone (PTH) concentrations were reduced, but the number of subjects with PTH below the lower limit for CKD stage 3 increased equally with both doses. Conclusions: Vitamin D insufficiency/deficiency in CKD significantly improved after the 12-month cholecalciferol treatment, with higher dose being more effective and equally safe. Further studies of vitamin D3 effects on bone metabolism are warranted.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266–281.
  2. Zadshir A, Tareen N, Pan D, Norris K, Martins D: The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005;15(suppl 5):97–101.
  3. Tareen N, Martins D, Zadshir A, Pan D, Norris KC: The impact of routine vitamin supplementation on serum levels of 25(OH)D3 among the general adult population and patients with chronic kidney disease. Ethn Dis 2005;15(suppl 5):102–106.
  4. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study. Am J Nephrol 2004;24:503–510.
  5. Okša A, Spustová V, Krivošíková Z, Gazdíková K, Fedelešová V, Štefíková K, Bernasovská G, Žilinská Z, Dzúrik R: Vitamin D deficiency in patients with chronic renal disease in stages 2–4 K/DOQI (in Slovak). Akt Nefrol 2006;12:45–51.
  6. Vecino-Vecino C, Gratton M, Kremer R, Rodriguez-Manas L, Duque G: Seasonal variance in serum levels of vitamin D determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. Gerontology 2006;52:33–39.
  7. Goodman WG, London G; on behalf of the Vascular Calcification Work Group: Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43:572–579.
  8. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42(suppl 3):S1–S201.

    External Resources

  10. Ishimura E, Nishizawa Y, Inaba M, et al: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55:1019–1027.
  11. Sulková S, Fořtová M, Uhrová J, Zima T: An importance of vitamin D metabolites assessment in patients with impaired renal function. Vnitř Lék 2004;50:510–518 (in Czech).
  12. LaClair RE, Hellman RN, Karp SL, et al: Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005;45:1026–1033.
  13. DeVille J, Thorp ML, Tobin L, et al: Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 2006;11:555–559.
  14. Zisman AL, Hristova M, Tammy Ho L, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007;27:36–43.
  15. Trizna W, Edwards RM: Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology 1991;42:91–96.
  16. Hathcock JN, Shao A, Vieth R, Heaney R: Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6–18.
  17. Imura A, Tsuji Y, Murata M, et al: α-Klotho as a regulator of calcium homeostasis. Science 2007;316:1615–1618.
  18. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6:162–169.
  19. Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31–38.
  20. Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O’Riordan JL: Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet 1980;ii:612–615.
  21. Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205–2215.
  22. Sommer S, Berndt T, Craig T, Kumar R: The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007;103:497–503.
  23. Hayashi M, Tsuchiya Y, Itaya Y, et al: Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 2004;19:2067–2073.
  24. Coburn JW, Maung HM, Elangovan L, et al: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877–890.
  25. Coyne D, Acharya M, Qiu P, et al: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006;47:263–276.
  26. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ: 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006;70:654–659.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50